Trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Phase 2 trial in which treatment after cycle 12 depends on undetectable minimal residual disease in blood and bone marrow. The registry primary outcome is undetectable MRD by flow cytometry in the bone marrow. ClinicalTrials.gov lists the study as recruiting.
Paolo Ghia
Phase 2 trial of MRD-guided post-transplant maintenance. The registry primary outcome is conversion from MRD-positive to MRD-negative complete response. ClinicalTrials.gov lists the study as recruiting.
M.D. Anderson Cancer Center
Phase 2 feasibility trial of a ctDNA and FDG-PET interim response-adapted approach for primary therapy of diffuse large B-cell lymphoma. ClinicalTrials.gov lists the study as recruiting.
University Health Network, Toronto
Phase 2 trial in which people with a radiographic complete response but detectable ctDNA receive mosunetuzumab, and those with undetectable ctDNA are observed. The registry primary outcome is the ctDNA clearance rate. ClinicalTrials.gov lists the study as recruiting.
Danielle Wallace
Phase 3 trial of MRD-guided maintenance after allogeneic transplant. The registry primary outcome is measurable residual disease recurrence-free survival. ClinicalTrials.gov lists the study as recruiting.
The First Affiliated Hospital of Soochow University